1. DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study. (15th January 2020) Authors: Sands, B E; Moss, A C; Armuzzi, A; Marshall, J K; Lindsay, J O; Sandborn, W J; Danese, S; Zeroncio, M; Modesto, I; Salese, L; Lawendy, N; Zhang, H; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme. (16th January 2018) Authors: Sands, B E; Taub, P R; Feagan, B G; Armuzzi, A; Friedman, G S; Moscariello, M; Lawendy, N; Pedersen, R D; Chan, G; Nduaka, C I; Quirk, D; Salese, L; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P252 Measuring the mediating effects of Mayo score components for tofacitinib on disease-specific quality of life in ulcerative colitis: data from the OCTAVE programme. (25th January 2019) Authors: Dubinsky, M; Bushmakin, A; DiBonaventura, M; Cappelleri, J; Salese, L; Maller, E; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P255 Perceived disease severity and treatment satisfaction among patients with ulcerative colitis in Europe. (25th January 2019) Authors: Armuzzi, A; Tarallo, M; Bargo, D; Lucas, J; Bluff, D; Hoskin, B; Salese, L; Cappelleri, J; Kayhan, C; DiBonaventura, M Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P260 An analysis of non-melanoma skin cancer rates in the tofacitinib Ulcerative Colitis clinical programme. (27th May 2021) Authors: Sands, B E; Cohen, R D; Ha, C; Reinisch, W; Salese, L; Mundayat, R; Lawendy, N; Panés, J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2. (15th January 2020) Authors: Dubinsky, M C; Hudesman, D P; Steinwurz, F; Kulisek, N; Salese, L; Paulissen, J; Su, C; Ponce de Leon, D; Magro, F Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open. (21st January 2022) Authors: Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 study. (30th January 2023) Authors: D'Haens, G; Afzali, A; Filip, R; Rolim, A; Terry, N A; Salese, L; Sahoo, A; Frustaci, M E; Yang, Z; Andrews, J M; Danese, S; Hisamatsu, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open. (21st January 2022) Authors: Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P516 Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials. (16th January 2018) Authors: Panés, J; Bressler, B; Colombel, J -F; Lawendy, N; Maller, E; Zhang, H; Woodworth, D A; Chan, G; Salese, L; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗